<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03109678</url>
  </required_header>
  <id_info>
    <org_study_id>AZ 107/02</org_study_id>
    <nct_id>NCT03109678</nct_id>
  </id_info>
  <brief_title>A Comparison of the Intubating Laryngeal Mask FASTRACH™ and the Intubating Laryngeal Mask Ambu Aura-i™</brief_title>
  <official_title>A Comparison of the Intubating Laryngeal Mask FASTRACH™ and the Intubating Laryngeal Mask Ambu Aura-i™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asklepios Kliniken Hamburg GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Kiel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asklepios Kliniken Hamburg GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intubating laryngeal mask Fastrach™ is considered a gold standard for blind intubation as
      well as for fibreoptic guided intubation via a laryngeal mask. Recently, a single use version
      of the mask has been introduced. The Fastrach single use laryngeal mask is beng compared to
      the new, low-priced single use intubating laryngeal mask Ambu Aura-i™.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eighty patients undergoing general anaesthesia with planned tracheal intubation for elective
      surgical procedures are enrolled in the study after checking for inclusion and exclusion
      criteria. Patients are randomised to either LMA group for blind tracheal intubation with
      either a standard PVC tracheal tube, or a specifically for the LMA Fastrach developed tube,
      yielding 4 subgroups.

      After a standardised anaesthesia induction, blind intubation is performed in each study
      group. Different time intervals are documented, such as time to first adequate lung
      ventilation, or f.e. time for laryngeal mask placement. A crossover-design is performed after
      unsuccessful intubation, using the alternate LMA or the other tracheal tube. LMA placement is
      visualised by fibreoptic control.

      An estimated success rate for blind intubation of 60% in the Aura-i group versus 90% in the
      Fastrach group yields a sample size of n= 38. To compensate for dropouts, n=40 subjects are
      enrolled in each group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 12, 2011</start_date>
  <completion_date type="Actual">March 7, 2012</completion_date>
  <primary_completion_date type="Actual">March 7, 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>success rate of blind intubation</measure>
    <time_frame>through study completion; time frame for individual study patient: two attempts of blind tracheal intubation peri-interventional, time maximum of 300 seconds</time_frame>
    <description>overall success rate of blind tracheal intubation within two attempts using either the FASTRACH™ laryngeal mask or the Ambu Aura-i™ laryngeal mask</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>influence of tracheal tubes</measure>
    <time_frame>through study completion; time frame for individual study patient: two attempts of blind tracheal intubation peri-interventional, time maximum of 300 seconds</time_frame>
    <description>influence of success rates of blind tracheal intubation using different tracheal tubes (Rüsch or LMA-ETT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>equivalence of the laryngeal masks regarding fibreoptic visualisation</measure>
    <time_frame>through study completion; after placing the laryngeal mask and checking for airway leak pressure, fibreoptic visualisation is performed within 60 seconds</time_frame>
    <description>fibreoptic control of laryngeal mask placement (Fastrach and Aura-i); the position of the larynx relative to the laryngeal cuff and mask-aperture is visualised and categorised as &quot;correct&quot;, &quot;lateral deviation&quot;, &quot;epiglottic downfolding&quot; or &quot;not assessable&quot;; additionally, the view on the larynx comparable to Cormack/Lehane score is recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subjective handling score</measure>
    <time_frame>through study completion; the handling of the laryngeal masks during the first placement attempt within 60 seconds; directly after placing laryngeal masks and before fibreoptic visualisation, the subjective handling score is documented as above</time_frame>
    <description>subjective handling score for the two compared laryngeal masks, rated as excellent (1) - poor (4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>differences in airway leak pressure</measure>
    <time_frame>through study completion; right after placing the laryngeal mask and checking for correct positioning, ALP is documented within 60 seconds</time_frame>
    <description>differences in airway leak pressure (ALP) of the two compared laryngeal masks, in cm H2O; presence of audible leakage as well as the absence of corresponding pressure increase on the monitor recorded by setting the APL valve to 40cm H2O, and fresh gas flow at 3l/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of postoperative sore throat and hoarseness</measure>
    <time_frame>patient interview 24 hours post procedural</time_frame>
    <description>incidence of postoperative sore throat and hoarseness as well as difficulty swallowing as reported by the study patients (&quot;none&quot;, &quot;moderate&quot;, &quot;severe&quot;)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Airway Management</condition>
  <condition>Laryngeal Mask Airway</condition>
  <condition>Fibreoptic Intubation</condition>
  <arm_group>
    <arm_group_label>Aura-i / Rüsch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blind tracheal intubation: Combination of laryngeal mask Ambu Aura-i™ with Rüsch Super Safety Silk™ tracheal tube</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aura-i / LMA ETT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blind tracheal intubation: Combination of laryngeal mask Ambu Aura-i™ with LMA ETT™ tracheal tube</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fastrach / Rüsch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blind tracheal intubation: Combination of laryngeal mask Fastrach™ with Rüsch Super Safety Silk™ tracheal tube</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fastrach / LMA ETT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blind tracheal intubation: Combination of laryngeal mask Fastrach™ with LMA ETT™ tracheal tube</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Crossover Ambu Aura-i™ / Rüsch Super Safety Silk™</intervention_name>
    <description>After unsuccessful blind intubation in the Ambu Aura-i™ / Rüsch Super Safety Silk™ group: crossover design using the Ambu Aura-i™ mask in combination with the LMA ETT™ tracheal tube</description>
    <arm_group_label>Aura-i / Rüsch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Crossover Ambu Aura-i™ / LMA ETT™</intervention_name>
    <description>After unsuccessful blind intubation in the Ambu Aura-i™ / LMA ETT group: crossover design using the Ambu Aura-i™ mask in combination with the Rüsch Super Safety Silk™ tracheal tube</description>
    <arm_group_label>Aura-i / LMA ETT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Crossover FASTRACH™ / Rüsch Super Safety Silk™</intervention_name>
    <description>After unsuccessful blind intubation in the FASTRACH™ / Rüsch Super Safety Silk™ group: crossover design using the FASTRACH™ mask in combination with the LMA ETT™ tube</description>
    <arm_group_label>Fastrach / Rüsch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Crossover FASTRACH™ / LMA ETT™</intervention_name>
    <description>After unsuccessful blind intubation in the FASTRACH™ / LMA ETT™ group: crossover design using the FASTRACH™ mask in combination with the Rüsch Super Safety Silk™ tube</description>
    <arm_group_label>Fastrach / LMA ETT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing planned general anaesthesia

          -  planned tracheal intubation

          -  elective surgical procedure

          -  15 to 80 years of age

        Exclusion Criteria:

          -  ASA physical status IV and V

          -  severe pulmonary comorbidity (COPD GOLD &gt;III, bronchial asthma)

          -  indication for rapid-sequence induction

          -  mouth opening (interincisor distance) &lt;3cm

          -  morbid obesity (BMI &gt;35kg.m-2)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Berthold Bein, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Asklepios Kliniken Hamburg GmbH</affiliation>
  </overall_official>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2017</study_first_submitted>
  <study_first_submitted_qc>April 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asklepios Kliniken Hamburg GmbH</investigator_affiliation>
    <investigator_full_name>Dr. Robert Schiewe</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

